Navigation

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142) [ID541]

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142)

Status: In development
Expected date of issue: August 2014
Process: MTA
Topic area:
  • Blood and immune system
  • Endocrine, nutritional and metabolic
 

NICE project team

Executive Lead: Carole Longson
Technical Lead: Nwamaka Umeweni
Communications manager: Shalu Kanal
Project manager:

Jeremy Powell

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 25 September 2013
1st appraisal committee meeting: 19 March 2014
2nd appraisal committee meeting: 21 May 2014
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Amgen (darbepoetin alfa, Aranesp)
  • Hospira (epoetin zeta, Retacrit)
  • Janssen-Cilag (epoetin alfa, Eprex)
  • Roche Products (epoetin beta, NeoRecormon)
  • Sandoz (epoetin alfa, Binocrit)

Patient/carer groups

  • Leukaemia Cancer Society
  • Leukaemia CARE
  • Myeloma UK
  • Target Ovarian Cancer

Professional groups

  • British Society for Haematology
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • NHS England
  • Welsh Assembly Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Hospital Information Services (Jehovah’s Witnesses)
  • Medicines and Healthcare products Regulatory Agency

Comparator manufacturers

  • None

Relevant research groups

  • Cochrane Haematological Malignancies Group
  • MRC Clinical Trials Unit

Assessment Group

  • Peninsula Technology Assessment Group, University of Exeter

Associated guideline groups

  • National Collaborating Centre for Cancer

Top


 

Key documents

This page was last updated: 15 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.